Biosyent (TSE:RX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioSyent Inc. has reported significant growth in Q2 and H1 of 2024, with record-high Canadian Pharma and Total Company sales, along with increased EBITDA and net income. The company’s strategic initiatives included promoting new brands and in-licensing a promising endocrinology product expected to bolster future revenues.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.